DelveInsight’s, “Spasticity Pipeline Insight” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Spasticity pipeline landscape. It covers the Spasticity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Spasticity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Spasticity Pipeline Report to explore emerging therapies, key Spasticity Companies, and future Spasticity treatment landscapes @ Spasticity Pipeline Outlook Report

 

Key Takeaways from the Spasticity Pipeline Report

• In January 2025:- Ipsen:- The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
• In January 2025:- Chongqing Claruvis Pharmaceutical Co., Ltd.:- This is a randomized, double-blind, dose escalation, placebo- and active-controlled parallel-group multi-center phase II study to evaluate the efficacy and safety of Recombinant Botulinum Toxin Type A (YY001) for injection in the treatment of upper limb spasticity in adults.
• In January 2025:- Pacira Pharmaceuticals Inc.:- This multicenter, randomized, double-blind, sham-controlled study is designed to evaluate the efficacy and safety of the iovera° system in subjects with upper extremity spasticity. A total of approximately 132 subjects will be enrolled; 88 subjects will receive treatment with the iovera° system and 44 subjects will receive sham treatment (sham iovera° system treatment).
• DelveInsight’s Spasticity pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Spasticity treatment.
• The leading Spasticity Companies such as RVL Pharmaceuticals, Huons, Bionorica SE, Supernus Pharmaceuticals, Saol Therapeutics, Revance Therapeutics, Flex Pharma, Canbex Therapeutics, Ipsen, Lundbeck A/S, CKD Bio Corporation, Sentynl Therapeutics, Shionogi, Lexicon Pharmaceuticals, Incannex, Delpor, Ethicann Pharmaceuticals and others.
• Promising Spasticity Therapies such as IPN10200, SL-1002, SPARC0921, Tizanidine, Moxifloxacin and others.

 

Discover how the Spasticity treatment paradigm is evolving. Access DelveInsight’s in-depth Spasticity Pipeline Analysis for a closer look at promising breakthroughs @ Spasticity Clinical Trials and Studies

 

Spasticity Emerging Drugs Profile

 

• HU-014: Huons

HU-014 (Liztox) is a newly developed Botulinum toxin A. Botulinum toxin dose is measured in units (U) based on the median lethal dose (LD50) of the neurotoxin. HU-014 is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum, the bacterium responsible for botulism. The botulinum toxin weakens or paralyzes skeletal muscle by inhibiting neurotransmission between peripheral nerve endings and muscle fibers. The effects of botulinum toxin are transient; muscular function typically returns to baseline within a few months.

 

• Myobloc: Supernus Pharmaceuticals

Myobloc (rimabotulinumtoxinB) injection is the first and only approved botulinum toxin Type B injectable indicated for the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults and the treatment of chronic sialorrhea in adults. MYOBLOC blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic-nerved terminals. Currently it is being evaluated in Phase II/III clinical trials to treat upper and lower limb spasticity.

 

Get a detailed analysis of the latest innovations in the Spasticity pipeline. Explore DelveInsight’s expert-driven report today! @ Spasticity Unmet Needs

 

Spasticity Companies

RVL Pharmaceuticals, Huons, Bionorica SE, Supernus Pharmaceuticals, Saol Therapeutics, Revance Therapeutics, Flex Pharma, Canbex Therapeutics, Ipsen, Lundbeck A/S, CKD Bio Corporation, Sentynl Therapeutics, Shionogi, Lexicon Pharmaceuticals, Incannex, Delpor, Ethicann Pharmaceuticals and others.

 

Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

 

Spasticity Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Spasticity Market Drivers and Barriers, and Future Perspectives

 

Scope of the Spasticity Pipeline Report

• Coverage- Global
• Spasticity Companies- RVL Pharmaceuticals, Huons, Bionorica SE, Supernus Pharmaceuticals, Saol Therapeutics, Revance Therapeutics, Flex Pharma, Canbex Therapeutics, Ipsen, Lundbeck A/S, CKD Bio Corporation, Sentynl Therapeutics, Shionogi, Lexicon Pharmaceuticals, Incannex, Delpor, Ethicann Pharmaceuticals and others.
• Spasticity Therapies– IPN10200, SL-1002, SPARC0921, Tizanidine, Moxifloxacin and others.
• Spasticity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Spasticity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Which companies are leading the race in Spasticity drug development? Find out in DelveInsight’s exclusive Spasticity Pipeline Report—access it now! @ Spasticity Emerging Drugs and Major Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. Spasticity Overview
4. Spasticity Pipeline Therapeutics
5. Spasticity Therapeutic Assessment
6. Spasticity – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. HU-014: Huons
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. Myobloc: Supernus Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Mid- Stage Products (Phase II)
14. LX-9211: Lexicon Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Lu AG06466: Lundbeck A/S
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Spasticity Key Companies
24. Spasticity Key Products
25. Spasticity Unmet Needs
26. Spasticity Market Drivers
27. Spasticity Market Barriers
28. Spasticity Future Perspectives and Conclusion
29. Spasticity Analyst Views
30. Spasticity Companies
31. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/knee-reconstruction-devices-market